Luther Birdzell, founder and CEO of Houston-based OAG Analytics is on a mission to democratize data for his upstream oil and gas clients. Courtesy of OAG Analytics

Luther Birdzell has been on a mission to democratize data for the upstream oil and gas industry since he started his company, OAG Analytics, in 2013.

For him, there's just not enough data scientists for hire to do the same thing internally for different companies. He thought of a way where he can give clients an easy-to-use platform to have access to data that could save oil and gas companies millions of dollars. So, that's exactly what he did.

"Over the past five and a half years, we've built that platform," Birdzell says. "We are currently helping to optimize over $1 billion in capital deployment around drilling and completions."

The company has grown to 25 employees and tripled its revenue last year. The team is forecasting another year of high grow for 2019.

Birdzell spoke with InnovationMap to talk about his start in software, the company's growth, and why nonprofit work has been important to him as a business leader.

InnovationMap: Did you always know you wanted to be an entrepreneur?

Luther Birdzell: When I was about two years old, my grandfather ran a meat business in New York City — in the meatpacking district, back when that area actually had meat packers. It just was in my bones from a really young age that I wanted to start a business.

IM: How did you get into software development?

LB: I studied electrical engineering in college. For my first seven years, I worked within consulting, implementing systems that made data more valuable to subject matter experts. I was primarily supporting management teams and mostly tech teams.

Then, I met the founders of iTKO, who were doing software testing for clients, and I helped them figure out a way that was complementary to what they were doing. We took a capability that can enable software developers that can help companies reduce their data center costs by a lot. It was a capability that was really restricted to specialized programing. Together we figured out how to make that a capability that anyone in an IT company used. That resulted in companies being able to higher fewer people to maintain servers, as well as reduce other costs. Companies were saving of millions of dollars per year per project.

IM: When did the idea for OAG come to you?

LB: Computer Associates bought iTKO from us in 2011. When I resigned from CA in 2013, it was very clear to me that artificial intelligence, big data, machine learning, and the cloud, were all tech ingredients for adding more value to data. Then the oil and gas business came into focus.

When I founded OAG Analytics, our mission then — and still is today — was to build a platform for the upstream oil and gas industry that enables them to manage their data, introduces world-class machine learning in minutes without having to write a single line of code, and allow them to run simulations on the resulting analysis.

IM: What makes OAG successful?

LB: My vision was to create a platform that could be trusted to support billions of dollars of capital optimization through transparency and control. A black box doesn't work for the kind of problems we're helping our customers optimize. They need something that's easy to use, simple, powerful, and also gives them complete control.

IM: What's the barrier of success for your clients?

LB: We have customers who have increased their capital efficiency on drilling programs that are about $500 million by over 25 percent, while still getting the same amount of oil out of the ground.

IM: What was the early reception like?

LB: We found a lot of interest in talking about how it works. In 2013, 2014, 2015, well over half the industry knew enough about this technology from other industries to have high confidence that it would affect the oil and gas industry one day. They were willing to spend an hour or two on what it is and how it works. But the number of companies who were really willing to invest in a meaningful way was really small.

There were companies, like EOG Resources, for example started spending millions of dollars developing this technology in house. Other companies seeing EOG and Anadarko success, raised the bar on the level of proof.

There's an increasing number of companies in the industry who realize that AI isn't a futuristic thing anymore. There are companies using it today, and the companies using it right are making more money. But, they're learning it's hard to do right. It could take years and millions of dollars to develop this yourself, but we're helping companies get up to speed in a matter of months, and our total cost for the first year is well under a million bucks to do this. They want us to train them how to use it, then act as support, rather than run it all for them.

IM: Do you plan to stay in just upstream oil and gas?

LB: We're 100 percent focused on upstream oil and gas, and always have been, but as we continue to grow, we're going to follow the market and what customers want. Repurposing our platform for other applications in oil and gas, energy, and even beyond that. We're evaluating. The vision has always been to democratize AI, and oil and gas is where we started.

IM: Do you have an exit strategy?

LB: As far as exits, I get asked this a lot. I don't believe in exit strategies. I believe in building a great company. I've seen a lot of founders make a lot of mistakes trying to cut corners to get to early exits. Our goal is to be a great company, and that starts with the right vision and then getting the right people and hires.

IM: How has Houston been as a place to have a startup in energy?

LB: Houston is unparalleled in the oil patch or the ability to support day trips. There's two airports and tons of direct flights to other cities in the oil patch. It's the only city you can cover all the other cities from with day trips. The efficiency of being able to be on site with customers is such an advantage.

There are a lot of industry experts in and around Houston, but a startup software company works very differently from an oil company. I think we have a long road ahead of us before we have an ecosystem in place to support startups and give them the best chance of success. Some of that comes from advisers, some from the ecosystem, and some part of it just takes time. But once those pieces come into play, talent follows. I think Houston is a very natural hub for energy tech.

IM: Volunteering is an important part of your business. Why is that something you've focused on?

LB: Something in the DNA of our business is giving back. We do that through direct community action. We've volunteered as a company, and we're always on the lookout for ways we can engage with and make the most contribution to the community. We do this primarily for personal reasons, but the universe has been very generous over my career with reciprocating a professional upside.

You volunteer in high school to get into college, then maybe some in college. And you might think, "oh that's for philanthropists or retired people and I'll get back to that later." But the reality of that is it feels better doing some of that now, so we do.

------

Portions of this interview have been edited.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.